Close Menu

HER2 Biomarkers

News and reporting on HER2 biomarkers.

Data showed that patients who had pathologic complete response in the neoadjuvant setting after treatment with a regimen containing Genetech's Perjeta experienced better progression-free and disease-free survival.

NEW YORK (GenomeWeb) – Roche this week announced plans to acquire Seragon Pharmaceuticals, aiming to bolster its own breast cancer pipeline and improve the standard of care for hormone receptor-positive breast cancer.

A new study using gene expression profiling to divide patients from an adjuvant trastuzumab (Herceptin) clinical trial into subgroups based on their response to the drug has shown that adjuvant treatment in addition to chemotherapy might be effective even in HER2-negative patient

The American Society for Clinical Oncology and the College of American Pathologists have jointly issued updated guidelines in which they continued to recommend that oncolo

The US Food and Drug Administration has accepted a supplemental biologics license application for Perjeta (pertuzumab) as a neoadjuvant treatment for women with HER2-positive, early-stage breast cancer, Roche subsidiary Genentech announced this week.

A flurry of recently published peer-reviewed papers has demonstrated the growing breadth and diversity of applications for Bio-Rad's QX100 Droplet Digital PCR system.

Originally published June 3.
CHICAGO – Based on promising results from earlier studies, Pfizer is moving ahead with a Phase III trial to study the investigational agent palbociclib in estrogen receptor-positive, HER2-negative breast cancer patients.

In the first quarter of this year, pharmacogenetically targeted cancer drugs Xalkori and Zelboraf had marked increases in revenues from the previous year's quarter.

NEW YORK (GenomeWeb News) – Biomarker-based diagnostics company Nuclea Biotechnologies today announced a partnership with Wilex aimed at better managing the treatment of metastatic breast cancer.

The US Food and Drug Administration last week approved Roche/Genentech's latest HER2-targeting breast cancer drug, trastuzumab emtansine (T-DM1).

Pages

The Guardian reports that visa costs could prevent scientists and others from coming to the UK.

The Trump Administration is reconsidering its plan to issue an executive order to require federally funded research to be freely available upon publication, Times Higher Education reports.

Nature News says some preprint repositories may close down due to a lack of funds to cover costs.

In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.